{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:56:58Z","timestamp":1794841018229,"version":"4.9.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004224","name":"Peter MacCallum Cancer Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004224","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eururo.2025.08.015","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T20:25:16Z","timestamp":1761769516000},"page":"74-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617"],"prefix":"10.1016","volume":"90","author":[{"given":"Heidi","family":"Fettke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6072-5175","authenticated-orcid":false,"given":"Louise","family":"Kostos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Docanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Bukczynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Medhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyah","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n C.","family":"Eliceiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathya","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siavash","family":"Foroughi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu","family":"Nguyen-Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.08.015_b0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.08.015_b0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.08.015_b0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.08.015_b0020","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2967\/jnumed.119.236414","article-title":"Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase ii prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer","volume":"61","author":"Violet","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.015_b0025","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","volume":"109","author":"Wyatt","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2025.08.015_b0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.eururo.2020.03.044","article-title":"Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multianalyte liquid biopsy assay for metastatic prostate cancer","volume":"78","author":"Fettke","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.015_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2025.08.015_b0040","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1200\/JCO.2024.42.16_suppl.5055","article-title":"Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)","volume":"42","author":"Kwan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2025.08.015_b0045","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2024.42.16_suppl.5008","article-title":"Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore","volume":"42","author":"Bono","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.08.015_b0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2144\/btn-2020-0045","article-title":"Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay","volume":"69","author":"Fettke","year":"2020","journal-title":"BioTechniques"},{"key":"10.1016\/j.eururo.2025.08.015_b0055","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nature Commun"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2025.08.015_b0060","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1200\/JCO.2023.41.16_suppl.5028","article-title":"Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: preliminary results","volume":"41","author":"Herrmann","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.08.015_b0065","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.08.015_b0070","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1200\/PO.20.00047","article-title":"Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer","volume":"4","author":"Dang","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2025.08.015_b0075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","article-title":"Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with lutetium-177-PSMA-617","volume":"57","author":"Crumbaker","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.08.015_b0080","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2967\/jnumed.123.266167","article-title":"Prediction of resistance to 177Lu-PSMA therapy by assessment of baseline circulating tumor DNA biomarkers","volume":"64","author":"Sartor","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.015_b0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","article-title":"Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)","volume":"48","author":"Ahmadzadehfar","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.08.015_b0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00259-017-3848-4","article-title":"PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and\/or enzalutamide. A retrospective analysis of overall survival","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.08.015_b0095","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00259-017-3751-z","article-title":"177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer","volume":"44","author":"Br\u00e4uer","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.08.015_b0100","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/cancers12051078","article-title":"Clinical variables associated with PSA response to lutetium-177-PSMA ([177Lu]-PSMA-617) radionuclide treatment in men with metastatic castration-resistant prostate cancer","volume":"12","author":"Gadot","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2025.08.015_b0105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2967\/jnumed.122.264398","article-title":"Evaluation of 177Lu-PSMA-617 SPECT\/CT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)","volume":"64","author":"Pathmanandavel","year":"2023","journal-title":"J Nucl Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825005019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825005019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:38:48Z","timestamp":1783017528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825005019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0302283825005019"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.08.015","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}